Resultados de la búsqueda - Portal de Modelos de Datos Médicos (MDM-Portal)

Eligibility Acute Myocardial Infarction NCT00187460

- 20/9/21 - 1 formulario, 2 itemgroups, 17 items, 1 idioma

Itemgroups: Inclusion Criteria, Exclusion Criteria

Study of the Effectiveness of Report Cards on the Quality of Care for Heart Attack and Heart Failure Patients; ODM derived from: https://clinicaltrials.gov/show/NCT00187460

Excerpt TIMI 46 Acute Coronary Syndrome NCT00402597 - ATLAS ACS TIMI 46

- 17/9/21 - 1 formulario, 66 itemgroups, 301 items, 1 idioma

Itemgroups: Subject Identification, Date of Visit, Demographics, Inclusion/Exclusion Criteria, Index ACS Event, Hospital Discharge for Index Event, Medical History of Special Interest, Vital Signs at Screening, Vital Signs, Physical Examination, Study Medication Review, First Dose of Study Medication, Concomitant Therapy, Aspirin Concomitant Therapy, Thienopyridine, Unfractionated Heparin, Low Molecular Weight Heparin, Parenteral Anticoagulant, Oral Anticoagulant, GP IIb/IIIa Inhibitor, Fibrinolytic, ECG, Unscheduled ECG, DNA Sample, DNA Sample Consent Modification, DNA Sample Replacement, Neurological Exam/Modified Rankin Scale, Seattle Angina Questionnaire, Echocardiogram, Holter, Medication Kit Number, Central Lab Sample Collection, PK/PD Sample Collection, End of Screening / Randomization, End of Treatment / Early Withdrawal, End of Follow-up, CEC Adjudicated Form, Death Adjudication, Myocardial Infarction, Severe Recurrent Ischemia Adjudication, Stroke Adjudication, NON-CNS Systemic Embolization Adjudication, Clinically Significant Bleeding Event Adjudication Form, Stent Thrombosis Adjudication, Canadian Cardiovascular Society Classification of Angina, Events and Procedures Review, Death, Cardiac Ischemic Events, Coronary Revascularization, Coronary Revascularization Prior to Signed Informed Consent, Local Cardiac Biomarker Measurements, Blood Transfusion, Stroke/TIA Events, Hemorrhage, Local Hematology Measurements, Non-CNS Systemic Embolization Events, Other Adverse Events, Local Lab, Health Resource Utilization Review, Emergency Room Visits, Hospitalization, Urgent Care or Physician Office Visit, Skilled Nursing/Rehabilitation Facility, Rehabilitation (Outpatient), Home Care Visits, Investigator Signature

ATLAS ACS-TIMI 46 compared the safety and efficacy of rivaroxaban, an oral direct factor Xa inhibitor, to placebo in patients with acute coronary syndromes. This is an excerpt, empty itemgroups have been added to flag missing items.

Excerpt PLATO Acute coronary Syndrome NCT00391872 - End of Treatment Visit

- 15/4/21 - 14 formularios, 10 itemgroups, 52 items, 1 idioma

Itemgroups: Visit, Clinical Events, Reminder, Procedures, Reminder, Overall Physical Examination, Vital Signs, Weight, Pregnancy Test, Electrocardiogram, NYHA - Heart Failure, EQ-5D Health-Related Quality of Life Questionnaire, Transition Antiplatelet Treatment

Ticagrelor is a new, reversible binding, anti-platelet medication. Anti-platelet medications work to prevent the formation of blood clots. Ticagrelor is being developed as a treatment for patients with acute coronary syndrome (ACS). ACS is a term that is used to describe both heart attacks in progress or the imminent threat of a heart attack. ACS is usually caused by the formation of a blood clot in an artery that partially or totally blocks the blood supply to a portion of the heart muscle. Ticagrelor will be compared with clopidogrel to determine which drug, when either is used in conjunction with aspirin, is better at reducing deaths from vascular causes, future heart attacks and/or strokes in patients with ACS. https://clinicaltrials.gov/ct2/show/NCT00391872

Section Investigational Products

5 itemgroups 4 items

Unscheduled Visit

6 itemgroups 40 items

Visit 4

5 itemgroups 39 items

Visit 2

6 itemgroups 37 items

Section Medication

2 itemgroups 2 items

Follow-up Visit

4 itemgroups 33 items

Eligibility Myocardial Infarction NCT01218815

- 5/11/20 - 1 formulario, 2 itemgroups, 18 items, 1 idioma

Itemgroups: Inclusion Criteria, Exclusion Criteria

Complete Infarct Related Artery Revascularization; ODM derived from: https://clinicaltrials.gov/show/NCT01218815

Eligibility Myocardial Infarction NCT00831116

- 8/1/19 - 1 formulario, 2 itemgroups, 9 items, 1 idioma

Itemgroups: Inclusion Criteria, Exclusion Criteria

An Observational Study of Cholesterol in Coronary Arteries; ODM derived from: https://clinicaltrials.gov/show/NCT00831116

Pharmacokinetics of an oral contraceptive co-administered with Albiglutide in women - 107032 - Adjudication Events - Acute Myocardial Infraction/Hospitalized Angina or Chest Pain

- 7/1/19 - 1 formulario, 12 itemgroups, 108 items, 1 idioma

Itemgroups: Administrative data, Acute Myocardial Infraction/Hospitalized Angina or Chest Pain, Clinical Presentation, Electrocardiographic Details, Cardiac Enzymes/Markers, CK-MB, Troponin I, Troponin T, Treatment Given for Acute MI/Hospitalized Angina/Chest Pain Event, Other Investigations Undertaken in View of this Event, Final Clinical Diagnosis, Narrative

Study ID: 107032 Clinical Study ID: GLP107032 Study Title: An open-label study to evaluate the pharmacokinetics of an oral contraceptive containing Norethindrone and Ethinyl Estradiol when co-administered with GSK716155 in healthy adult female subjects Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT01077505 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 1 Study Recruitment Status: Completed Generic Name: albiglutide Trade Name: Tanzeum,Eperzan Study Indication: Diabetes Mellitus, Type 2

Estimation of Dose Proportionality of Darapladib - 107038 - Follow-Up: 12-lead ECG Abnormalities

- 13/11/18 - 1 formulario, 8 itemgroups, 87 items, 1 idioma

Itemgroups: Administrative data, Record clinically significant abnormalities below., A. Rhythm, B. P-Wave Morphology, C. Conduction, D. Myocardial Infraction, E. Depolarisation/Repolarisation (QRS-T), F. Other

Study ID: 107038 Clinical Study ID: LPL107038 Study Title: Study to Estimate the Dose Proportionality of the Enteric-Coated Freebase Formulation of SB-480848 Patient Level Data: Clinicaltrials.gov Identifier: Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 1 Study Recruitment Status: Completed Generic Name: darapladib Trade Name: Tyrisa ,US Study Indication: Atherosclerosis